中国药促会宋瑞霖：如果手机价格被管控 就不会有今天的华为

Core Viewpoint - The key to the pharmaceutical industry's growth in China lies in improving market mechanisms, as highlighted by the comparison with successful companies like Huawei and BYD in other sectors [1]. Group 1: International Comparisons - The U.S. has successfully attracted significant investments from major pharmaceutical companies by establishing price benchmarks and tariff threats, with 60% of their profits coming from the U.S. market [1]. - In contrast, Europe’s social welfare policies have led to a "decentralization" of the pharmaceutical industry, with major companies like Roche and Novartis choosing to launch new drugs in the U.S. due to its larger and more attractive market [1][2]. - The UK's exit from the EU has resulted in reduced market attractiveness, causing large pharmaceutical companies to reconsider their investments [1]. Group 2: Current State of China's Pharmaceutical Industry - China's innovation drug industry is currently mismatched with its market potential, as evidenced by the low per capita spending on innovative drugs compared to Japan, where per capita spending is 24.4 times higher despite a GDP that is only 3.9 times greater [2]. - The pricing logic for innovative drugs differs significantly between China and the U.S., with China initiating price negotiations at the outset, leading to immediate price reductions upon market entry [2]. Group 3: Challenges in Commercialization - While China excels in the invention and transformation stages of the pharmaceutical chain, it struggles in the commercialization phase, often acting merely as a "project provider" due to insufficient market support [3]. Group 4: Recommendations for Improvement - Two core recommendations were proposed: 1. Reform the entry and evaluation mechanisms for innovative drug insurance, suggesting a direct connection between drug approval and insurance coverage, with a two-year evaluation period based on real-world data [4]. 2. Develop commercial health insurance significantly, with a proposed model that could generate over 3.4 trillion yuan annually if 350 million middle-class individuals contribute 800 yuan monthly [5]. Group 5: Economic Impact - If China's innovative drug payment system could reach the level of Japan's, the pharmaceutical industry could become a true economic pillar, allowing companies to pay more taxes and better support public welfare [5].